Desmopressin Acetate interactions

Food & lifestyle

• food

  Minor

  Absorption

  Food may decrease the rate and extent of absorption of desmopressin following oral administration.

  What to do: This interaction has a low clinical impact in most patients, especially since oral desmopressin is intended to be administered at bedtime.Nevertheless, the possibility of food effects should be considered before increasing the dose whenever a diminution of effect is noted. A significant interaction is not expected to occur with the sublingual formulation, since absorption occurs primarily in the oral mucosa, pharynx, and esophagus.

  3 sources

  1. "Product Information. DDAVP (desmopressin)." Rhone Poulenc Rorer (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):

Conditions

Conditions in which Desmopressin Acetate needs care, as documented in this source.

• Kidney Diseases

  Major

  The use of desmopressin is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).

  2 sources

  1. "Product Information. DDAVP (desmopressin)." Rhone Poulenc Rorer (2001):
  2. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals (2001):

• Water Intoxication

  Major

  Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

  8 sources

  1. "Product Information. Pitressin (vasopressin)." Parke-Davis (2001):
  2. "Product Information. DDAVP (desmopressin)." Rhone Poulenc Rorer (2001):
  3. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals (2001):
  4. Lin TW, Kuo YS "Acute pulmonary oedema following administration of vasopressin for control of massive GI tract haemorrhage in a major burn patient." Burns 22 (1996): 73-5
  5. Tulandi T, Beique F, Kimia M "Pulmonary edema: a complication of local injection of vasopressin at laparoscopy." Fertil Steril 66 (1996): 478-80
  6. Robson WLM "Water intoxication in patients treated with desmopressin." Pharmacotherapy 16 (1996): 969-70
  7. Williford SL "Water intoxication in patients treated with desmopressin - reply." Pharmacotherapy 16 (1996): 970
  8. Robson WLM, Norgaard JP, Leung AKC "Hyponatremia in patients with nocturnal enuresis treated with DDAVP." Eur J Pediatr 155 (1996): 959-62

• Thromboembolism

  Moderate

  Rare cases of thrombotic events (thrombosis, acute cerebrovascular thrombosis, and acute myocardial infarction) have been reported following desmopressin injection in patients predisposed to thrombus formation. Although a causal relationship has not been established, therapy with desmopressin should be administered cautiously in patients with a current or past history of thrombotic or thromboembolic disorders.

  3 sources

  1. "Product Information. DDAVP (desmopressin)." Rhone Poulenc Rorer (2001):
  2. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals (2001):
  3. Vermylen J, Peerlinck K "Fatal complication of desmopressin." Lancet 346 (1995): 447

• Vascular Diseases

  Moderate

  The use of desmopressin, primarily in parenteral administration and/or in large doses, has been infrequently associated with changes in blood pressure, causing either slight elevations or transient decreases with a compensatory increase in heart rate. Therapy with desmopressin, regardless of route of administration, should be administered cautiously in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

  2 sources

  1. "Product Information. DDAVP (desmopressin)." Rhone Poulenc Rorer (2001):
  2. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals (2001):